XSHE
002734
Market cap1.27bUSD
Oct 09, Last price
17.78CNY
1D
-0.78%
1Q
13.61%
Jan 2017
14.86%
IPO
249.31%
Name
Limin Group Co Ltd
Chart & performance
P/E
17.63
P/S
1.87
EPS
1.01
Div yield, %
1.40%
Shrs. gr., 5y
4.85%
Rev. gr., 5y
0.63%
Revenues
4.53b
+6.83%
Net income
480m
+489.70%
CFO
533m
+42.51%
Dividend
May 22, 20260.45 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Limin Group Co.,Ltd. engages in the research and development, production, and sale of fungicides, insecticides, herbicides, and biopesticides in China. The company offers various pesticides, including mancozeb, cymoxanil, fosetyl-aluminum, propineb, pyrimethanil, difenoconazole, m-phenylenediamine, chlorothalonil, thiacloprid, metiram, famoxadone, azoxystrobin, cyprodinil, folpet, captan, etc.; and veterinary drugs. The company was formerly known as Limin Chemical Co., Ltd. and changed its name to Limin Group Co.,Ltd. in January 2020. Limin Group Co.,Ltd. was founded in 1996 and is based in Xuzhou, China.
Key people
Chaohui Fan
President, Director · since 2021
Qing Zhang
Vice Chairman of the Board · since 2024
Shuyan Shen
Chief Financial Officer, Vice President · since 2021
Juncong Gao
Vice President · since 2024
Hao Wu
Secretary of the Board · since 2024
Xinan Chen
Vice President, Director · since 2024
Yuanyuan Li
Director · since 2021
Xinsheng Li
Chairman of the Board · since 2022
Jingquan Sun
Chief Engineer, Director · since 2021
Zhao Xu
Director · since 2024
Li Cheng
Independent Director · since 2021
Yaping Liu
Independent Director · since 2020
Jianping Ma
Independent Director · since 2024
Zhe Shen
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||